Table 1 The top 45 drugs associated with reports of drug-induced photosensitivity to the FDA from 2004–2023.
Drug Class | Reports (% of Total) | Reports from US(% of Class-Specific) | Maximum Drug-Induced Photosensitivity Reports (Year) | Female (%) | Median Age [IQR] | Average % Change per Year (95% CI), P value* | N(%) in 2004 | N(%) in 2023 |
|---|---|---|---|---|---|---|---|---|
Immunosuppressants | 2026(20.94%) | 1583(78.13%) | 283(2016) | 969(47.83%) | 35.5[26.5] | 0.01(0.00,0.01),p = 0.039 | 2(2.02%) | 77(15.01%) |
Monoclonal antibodies | 1942(20.07%) | 1432(73.74%) | 242(2022) | 1191(61.33%) | 46[46] | 0.01(0.00,0.02),p = 0.0156 | 22(22.22%) | 210(40.94%) |
Antineoplastic agentsa | 1528(15.79%) | 1054(68.98%) | 291(2016) | 831(54.38%) | 45[40] | 0.01(0.01,0.02),p < 0.0001 | 1(1.01%) | 77(15.01%) |
Antibacterials | 1085(11.21%) | 372(34.29%) | 126(2019) | 423(38.99%) | 68.5[21.5] | 0.00(-0.01,0.00),p = 0.0418 | 9(9.09%) | 84(16.37%) |
Psychoanaleptics | 1009(10.43%) | 537(53.22%) | 255(2016) | 707(70.07%) | 27[35] | – 0.02(-0.02,– 0.01),p < 0.0001 | 38(38.38%) | 17(3.31%) |
Anti-acne preparations | 594(6.14%) | 545(91.75%) | 163(2019) | 391(65.82%) | 51.5[39.5] | 0.00(0.00,0.01),p = 0.1946 | 4(4.04%) | 0(0.00%) |
Othersb | 476(4.92%) | 139(29.20%) | 103(2015) | 184(38.66%) | 63[22] | – 0.01 (-0.01, – 0.00), p = 0.0004 | 7(7.07%) | 29(5.65%) |
Emollients and protectives | 378(3.91%) | 370(97.88%) | 196(2014) | 191(50.53%) | 45.5[23.25] | 0.00(0.00,0.01),p = 0.6997 | 0(0.00%) | 0(0.00%) |
Cardiovascular system | 239(2.47%) | 37(15.48%) | 27(2018) | 80(33.47%) | 44.5[39.5] | 0.00(-0.01,0.00),p = 0.0002 | 9(9.09%) | 12(2.34%) |
Interferons | 212(2.19%) | 170(80.19%) | 74(2015) | 115(54.25%) | 52.5[30.5] | 0.00(0.00,0.00),p = 0.0343 | 4(4.04%) | 0(0.00%) |
HMG CoA reductase inhibitors | 186(1.92%) | 56(30.11%) | 23(2020) | 89(47.85%) | 47[37] | 0.00(0.00,0.00),p = 0.0022 | 4(4.04%) | 7(1.36%) |
Top 45 Overall Database from 2004–2023 | 9675(47.81%) | 6293 (65.04%) | 1156(2016) | 5171(53.45%) | 44[66.5] |
